My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

3 Biotech Stocks Using AI to Change Healthcare Forever ↗

July 14, 2023

These three biotech firms are leveraging artificial intelligence to revolutionize therapeutics and make disease a thing of the past.

Via InvestorPlace

Analyst Ratings for Blueprint Medicines ↗

July 14, 2023

Via Benzinga

Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront ↗

July 01, 2023

Via Talk Markets

ETF Returns: Mid-Cap Winners And Losers ↗

June 28, 2023

We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...

Via Benzinga

What Will AbbVie Buy Next? ↗

June 28, 2023

Two mid-cap drugmakers stand out as logical targets for AbbVie.

Via The Motley Fool

Analyst Expectations for Blueprint Medicines's Future ↗

June 14, 2023

Via Benzinga

FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients ↗

May 23, 2023

The U.S.

Via Benzinga

Analyst Expectations for Blueprint Medicines's Future ↗

May 23, 2023

Via Benzinga

Blueprint Medicines's Return On Capital Employed Overview ↗

May 15, 2023

Via Benzinga

3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon ↗

June 12, 2023

These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials.

Via InvestorPlace

Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 05, 2023

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.

Via Benzinga

EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday ↗

June 05, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Analyst Ratings for Blueprint Medicines ↗

May 05, 2023

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

April 19, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023 ↗

June 05, 2023

Via Benzinga

US Stocks Mixed; SAIC Posts Upbeat Results ↗

June 05, 2023

U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 05, 2023

Via Benzinga

Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday ↗

June 05, 2023

BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares...

Via Benzinga

16 Analysts Have This to Say About Blueprint Medicines ↗

March 30, 2023

Via Benzinga

FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study ↗

March 29, 2023

Via Benzinga

This Biotech Could Soon Go Parabolic, But Should You Buy It? ↗

June 04, 2023

Its situation is neither as good nor as bad as it might seem at first glance.

Via The Motley Fool

Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future ↗

May 23, 2023

Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Where Blueprint Medicines Stands With Analysts ↗

February 27, 2023

Via Benzinga

Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients ↗

February 27, 2023

Via Benzinga

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Earnings Preview For Blueprint Medicines ↗

February 15, 2023

Via Benzinga

Analyst Ratings for Blueprint Medicines ↗

January 23, 2023

Via Benzinga

Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines ↗

February 23, 2023

Via Benzinga

FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study ↗

February 10, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.